Needham Maintains Buy on Cytokinetics, Lowers Price Target to $72
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger maintains a Buy rating on Cytokinetics (NASDAQ:CYTK) but lowers the price target from $108 to $72.
May 23, 2024 | 10:55 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Needham analyst Serge Belanger maintains a Buy rating on Cytokinetics but lowers the price target from $108 to $72, indicating a more cautious outlook.
The maintained Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates a more cautious outlook, likely due to revised expectations or market conditions.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100